苯并噻吩-2-羧酸肼 | 175135-07-6

• 物质功能分类: 有机原料 - 肼或胲的有机衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 苯并噻吩-2-羧酸肼
• 中文别名: 苯并[b]噻吩-2-羧酰肼
• 英文名称: benzo[b]thiophene-2-carbohydrazide
• 英文别名: benzothiophene-2-carboxylic acid hydrazide；1-Benzothiophene-2-carbohydrazide
• CAS: 175135-07-6
• 化学式: C₉H₈N₂OS
• mdl: MFCD00052501
• 分子量: 192.241
• InChiKey: ZXKPFIRPUUAAPQ-UHFFFAOYSA-N

物化性质

• 熔点：
  176-178 °C
• 密度：
  1.367±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  避氧化物

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 安全说明：
  S26,S37/39
• 储存条件：
  保存方法：密闭、阴凉、通风干燥处。

SDS

Name:	benzo[b]thiophene-2-carbohydrazide Material Safety Data Sheet
Synonym:
CAS:	175135-07-6

Section 1 - Chemical Product MSDS Name:benzo[b]thiophene-2-carbohydrazide Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
175135-07-6	benzo[b]thiophene-2-carbohydrazide	97	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
The toxicological properties of this material have not been investigated. Use appropriate procedures to prevent opportunities for direct contact with the skin or eyes and to prevent inhalation.

---

Section 4 - FIRST AID MEASURES
Eyes: Not available.
Skin:
Not available.
Ingestion:
Not available.
Inhalation:
Not available.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
Not available.
Extinguishing Media:
Not available.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Not available.

---

Section 7 - HANDLING and STORAGE
Handling:
Not available.
Storage:
Not available.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Exposure Limits CAS# 175135-07-6: Personal Protective Equipment Eyes: Not available.
Skin:
Not available.
Clothing:
Not available.
Respirators:
Not available.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white - yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 240 - 242 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H5FN2O
Molecular Weight: 164

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Not available.
Incompatibilities with Other Materials:
Not available.
Hazardous Decomposition Products:
Not available.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 175135-07-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
benzo[b]thiophene-2-carbohydrazide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
WGK (Water Danger/Protection)
CAS# 175135-07-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 175135-07-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 175135-07-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  苯并噻吩-2-羧酸肼 在 sodium hydroxide 、 PS-supported BEMP 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 为溶剂， 反应 26.17h， 生成 4-{3-Benzo[b]thiophen-2-yl-5-[2-(1H-indol-3-yl)-ethylsulfanyl]-[1,2,4]triazol-4-yl}-butylamine
  参考文献：
  名称：

  3-Thio-1,2,4-triazoles, novel somatostatin sst2/sst5 agonists

  摘要：

  Novel 3-thio-1,2,4-triazoles have been obtained via a solution-phase parallel synthesis strategy, affording potent non-peptidic human somatostatin receptor subtypes 2 and 5 agonists. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.061
• 作为产物：
  描述：

  1-苯并噻吩-2-羧酸乙酯 在 一水合肼 作用下， 以 乙醇 为溶剂， 以90%的产率得到苯并噻吩-2-羧酸肼
  参考文献：
  名称：

  2-（1,3,4-恶二唑-2（3H）-硫酮）-3-氨基-5-芳基噻吩并[2,3-b]吡啶作为DRAK2抑制剂的合成及其构效关系研究

  摘要：

  近年来，DAPK相关的凋亡诱导蛋白激酶2（DRAK2）已成为治疗各种自身免疫性疾病和预防器官移植后移植排斥的有希望的靶标。但是，尚未发现用于发现DRAK2新型小分子抑制剂的药物化学优化方案。导致了苯并噻吩类似物的发现专有化合物文库的筛选，其中显示的亲和常数（ķ d 0.25μ）值中号。芯支架的变化时，可以得到一系列5- arylthieno [2,3-的取代模式的b ]与强的结合亲和力的吡啶（ķ d = 0.008μ中号代表最有力的代表）。这些化合物还显示出在功能生化DRAK2酶测定有前途的活性，与IC 50值的0.029μ中号为最有效的同类。最有效的化合物的选择性分析表明，它们在DAPK激酶家族中缺乏选择性。但是，效力较低的类似物之一是DRAK2的选择性配体，可以用作合成选择性有效的DRAK2抑制剂的起点。

  DOI：

  10.1002/cmdc.201402234

文献信息

• 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY 한국화학연구원(319980077651)

  公开号：KR20150134301A

  公开（公告）日：2015-12-01

  본 발명은 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명에 따른 화학식 1로 표시되는 신규한 화합물은 인플루엔자 바이러스에 대한 항바이러스 활성이 현저히 우수할 뿐만 아니라, 인간 세포에 대한 세포독성이 없어 인체에 부작용이 적으므로, 이를 유효성분으로 함유하는 약학적 조성물은 인플루엔자 바이러스 감염에 의해 발병되는 독감, 감기, 인후염, 기관지염, 폐렴, 조류독감, 돼지독감, 염소독감 등의 예방 또는 치료용 유용하게 사용될 수 있다.

  本发明涉及新型化合物或其药学上可接受的盐，以及含有该有效成分的用于预防或治疗由流感病毒感染引起的疾病的药学组合物。根据本发明的化学式1所示的新型化合物不仅对流感病毒具有显著优越的抗病毒活性，而且对人类细胞无细胞毒性，对人体副作用小，因此含有该有效成分的药学组合物可有效用于预防或治疗由流感病毒感染引起的流感、感冒、喉炎、支气管炎、肺炎、禽流感、猪流感、盐酸流感等疾病。
• Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof
  申请人：——

  公开号：US20020128292A1

  公开（公告）日：2002-09-12

  The present invention is directed to substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs thereof, represented by the general Formula I: 1 wherein X, Ar 1 , R 2 -R 6 and R 12 are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. The compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及取代的吲哚-2-羧酸亚苄基肼及其类似物，其由通式I表示： 1 其中X，Ar 1 ，R 2 -R 6 和R 12 的定义如本文中所述。本发明还涉及发现具有I式的化合物是半胱天冬酶的激活剂和凋亡的诱导剂。本发明的化合物可用于诱导在异常细胞不受控制的生长和扩散发生的多种临床状况中的细胞死亡。
• Microscale Parallel Synthesis of Acylated Aminotriazoles Enabling the Development of Factor XIIa and Thrombin Inhibitors
  作者：Simon Platte、Marvin Korff、Lukas Imberg、Ilker Balicioglu、Catharina Erbacher、Jonas M. Will、Constantin G. Daniliuc、Uwe Karst、Dmitrii V. Kalinin

  DOI：10.1002/cmdc.202100431

  日期：2021.12.14

  approach toward N-acylated aminotriazoles is reported, enabling the compounds’ screening against FXIIa and thrombin. This approach afforded low-nanomolar FXIIa and thrombin inhibitors with no off-targeting of the other tested serine proteases. Selected compounds were shown to be covalent inhibitors of FXIIa and demonstrated anticoagulant properties in vitro, influencing the intrinsic blood coagulation

  抗凝剂进展：报道了一种 N-酰化氨基三唑的微量平行合成方法，使该化合物能够针对 FXIIa 和凝血酶进行筛选。这种方法提供了低纳摩尔浓度的 FXIIa 和凝血酶抑制剂，且其他测试的丝氨酸蛋白酶没有脱靶。选定的化合物被证明是 FXIIa 的共价抑制剂，并在体外表现出抗凝血特性，影响内在的凝血途径。
• Design, Synthesis, and Pharmacological Evaluation of First‐in‐Class Multitarget <i>N</i> ‐Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors
  作者：Daniel A. Rodrigues、Fabiana S. Guerra、Fernanda S. Sagrillo、Pedro Sena M. Pinheiro、Marina A. Alves、Sreekanth Thota、Lorrane S. Chaves、Carlos M. R. Sant'Anna、Patrícia D. Fernandes、Carlos A. M. Fraga

  DOI：10.1002/cmdc.201900716

  日期：2020.3.18

  phosphatidylinositol 3-kinases (PI3Ks) is a very promising approach for cancer treatment. This manuscript describes the design, synthesis, in vitro pharmacological profile, and molecular modeling of a novel class of N-acylhydrazone (NAH) derivatives that act as HDAC6/8 and PI3Kα dual inhibitors. The surprising selectivity for PI3Kα may be related to differences in the conformation in the active site

  靶向组蛋白脱乙酰基酶（HDACs）和磷脂酰肌醇3-激酶（PI3Ks）是一种非常有前途的癌症治疗方法。该手稿描述了充当HDAC6 / 8和PI3Kα双重抑制剂的新型N-酰基hydr（NAH）衍生物的设计，合成，体外药理学特征和分子模型。对PI3Kα的惊人的选择性可能与活性位点的构象差异有关。细胞研究表明，这些化合物在HDAC6抑制和PI3 / K / AKT / mTOR途径中起作用。选择性抑制HDAC6 / 8和抑制PI3Kα的化合物显示出治疗癌症的潜力。
• PYRAZOLE COMPOUNDS AND USE THEREOF
  申请人：Takagi Masaki

  公开号：US20090036450A1

  公开（公告）日：2009-02-05

  The pyrazole compound of the present invention is represented by the following general formula (I). The pyrazole compound of the present invention or a salt thereof or a solvate thereof potently inhibits liver glycogen phosphorylase, and, therefore, is useful as a therapeutic or prophylactic agent for diabetes. wherein each symbol denotes as described in the specifications.

  本发明的吡唑化合物由以下一般式（I）表示。本发明的吡唑化合物或其盐或溶剂化物强力抑制肝糖原磷酸化酶，因此，可用作糖尿病的治疗或预防剂。其中，每个符号如规范中所述。

表征谱图